BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5:145-159. [PMID: 11218912 DOI: 10.1016/s1089-3261(05)70158-6] [Cited by in Crossref: 231] [Cited by in F6Publishing: 102] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Pan YX, Sun XQ, Hu ZL, Xie W, Nie KX, Fang AP, Zhang YY, Fu YZ, Chen JB, Wang JC, Wang X, Zhang YJ, Hu DD, Chen MS. Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients. J Hepatocell Carcinoma 2021;8:657-70. [PMID: 34235104 DOI: 10.2147/JHC.S316223] [Reference Citation Analysis]
2 Ma Y, Xu YC, Tang L, Zhang Z, Wang J, Wang HX. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol. 2012;1:11. [PMID: 23210562 DOI: 10.1186/2162-3619-1-11] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
3 Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Billingham LJ, Martin A, Beaugrand M, Johnson PJ. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer. 2006;94:287-292. [PMID: 16404431 DOI: 10.1038/sj.bjc.6602923] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
4 Neo SY, Leow CK, Vega VB, Long PM, Islam AF, Lai PB, Liu ET, Ren EC. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 2004;39:944-53. [PMID: 15057898 DOI: 10.1002/hep.20105] [Cited by in Crossref: 90] [Cited by in F6Publishing: 72] [Article Influence: 5.0] [Reference Citation Analysis]
5 Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583 [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.1007/bf03260065] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
7 Yen CJ, Ai YL, Tsai HW, Chan SH, Yen CS, Cheng KH, Lee YP, Kao CW, Wang YC, Chen YL, Lin CH, Liu T, Tsai HP, Wang JR, Su IJ, Huang W. Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection. Hepatology 2018;68:815-26. [PMID: 29350774 DOI: 10.1002/hep.29790] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
8 Amado V, González-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, Sánchez-Frías M, García-Jurado G, Montero JL, Ciria R, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. Cancers (Basel) 2021;13:2476. [PMID: 34069569 DOI: 10.3390/cancers13102476] [Reference Citation Analysis]
9 Liu Z, Chen M, Xie LK, Liu T, Zou ZW, Li Y, Chen P, Peng X, Ma C, Zhang WJ, Li PD. CLCA4 inhibits cell proliferation and invasion of hepatocellular carcinoma by suppressing epithelial-mesenchymal transition via PI3K/AKT signaling. Aging (Albany NY) 2018;10:2570-84. [PMID: 30312171 DOI: 10.18632/aging.101571] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
10 Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002;36:410-7. [PMID: 12143050 DOI: 10.1053/jhep.2002.34744] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 6.1] [Reference Citation Analysis]
11 Reghupaty SC, Sarkar D. Current Status of Gene Therapy in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1265. [PMID: 31466358 DOI: 10.3390/cancers11091265] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
12 Zhao WH, Ma ZM, Zhou XR, Feng YZ, Fang BS. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol 2002; 8(2): 237-242 [PMID: 11925599 DOI: 10.3748/wjg.v8.i2.237] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 49] [Article Influence: 2.6] [Reference Citation Analysis]
13 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
15 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
16 Allard MA, Sa Cunha A, Ruiz A, Vibert E, Sebagh M, Castaing D, Adam R. The postresection alpha-fetoprotein in cirrhotic patients with hepatocellular carcinoma. An independent predictor of outcome. J Gastrointest Surg. 2014;18:701-708. [PMID: 24402605 DOI: 10.1007/s11605-013-2433-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ma Y, Cui D, Zhang Y, Han CC, Wei W. Insulin-Like Growth Factor Binding Protein-2 Promotes Proliferation and Predicts Poor Prognosis in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:5083-92. [PMID: 32606730 DOI: 10.2147/OTT.S249527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, Peng BG. Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. Med Oncol. 2013;30:721. [PMID: 24026659 DOI: 10.1007/s12032-013-0721-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
19 Cheng Z, Yang P, Qu S, Zhou J, Yang J, Yang X, Xia Y, Li J, Wang K, Yan Z. Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection. HPB (Oxford). 2015;17:422-427. [PMID: 25421805 DOI: 10.1111/hpb.12367] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
20 Bang H, Ha SY, Hwang SH, Park CK. Expression of PEG10 Is Associated with Poor Survival and Tumor Recurrence in Hepatocellular Carcinoma. Cancer Res Treat 2015;47:844-52. [PMID: 25687862 DOI: 10.4143/crt.2014.124] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
21 Gao XH, Zhang SS, Chen H, Wang K, Xie W, Wang FB. Lipoprotein (a): a promising prognostic biomarker in patients with hepatocellular carcinoma after curative resection. Onco Targets Ther 2018;11:5917-24. [PMID: 30271176 DOI: 10.2147/OTT.S164273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Selleck MJ, Senthil M, Wall NR. Making Meaningful Clinical Use of Biomarkers. Biomark Insights. 2017;12:1177271917715236. [PMID: 28659713 DOI: 10.1177/1177271917715236] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
23 Xu XS, Qu K, Liu C, Zhang YL, Liu J, Song YZ, Zhang P, Liu SN, Chang HL. Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma. World J Gastroenterol 2012; 18(48): 7242-7250 [PMID: 23326129 DOI: 10.3748/wjg.v18.i48.7242] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
24 Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO. Gene expression patterns in human liver cancers. Mol Biol Cell. 2002;13:1929-1939. [PMID: 12058060 DOI: 10.1091/mbc.02-02-0023] [Cited by in Crossref: 359] [Cited by in F6Publishing: 434] [Article Influence: 18.0] [Reference Citation Analysis]
25 Komaki Y, Ozono Y, Nakamura K, Iwakiri H, Hasuike S, Sueta M, Miike T, Yamamoto S, Uto H, Kusumoto K, Ochiai T, Kato J, Komada N, Kuroki K, Eto T, Shigehira M, Hirono S, Nagata K, Kawakami H. Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older. BMC Gastroenterol 2022;22:210. [PMID: 35484503 DOI: 10.1186/s12876-022-02284-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Heinrich S, Sprinzl M, Schmidtmann I, Heil E, Koch S, Czauderna C, Heinrich B, Philippe P Diggs L, Wörns MA, Kloeckner R, Galle PR, Marquardt JU, Weinmann A. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterol J 2020;8:444-52. [PMID: 32213028 DOI: 10.1177/2050640620904524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Lu Q, Li J, Cao H, Lv C, Wang X, Cao S. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. Biosci Rep 2020;40:BSR20192424. [PMID: 32039435 DOI: 10.1042/BSR20192424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
28 Tao K, Bian Z, Zhang Q, Guo X, Yin C, Wang Y, Zhou K, Wan S, Shi M, Bao D, Yang C, Xing J. Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma. EBioMedicine 2020;56:102811. [PMID: 32512514 DOI: 10.1016/j.ebiom.2020.102811] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
29 Chin KM, Allen JC, Teo JY, Kam JH, Tan EK, Koh Y, Goh KPB, Cheow PC, Raj P, Chow KHP, Chung YFA, Ooi LL, Chan CY, Lee SY. Predictors of post-hepatectomy liver failure in patients undergoing extensive liver resections for hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg 2018;22:185-96. [PMID: 30215040 DOI: 10.14701/ahbps.2018.22.3.185] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
30 Manga YB, Ko F, Yang Y, Hung J, Yang W, Huang H, Wu C. Ultra-fast and sensitive silicon nanobelt field-effect transistor for high-throughput screening of alpha-fetoprotein. Sensors and Actuators B: Chemical 2018;256:1114-21. [DOI: 10.1016/j.snb.2017.10.007] [Cited by in Crossref: 8] [Article Influence: 2.0] [Reference Citation Analysis]
31 Li Y, Huang N, Wang C, Ma H, Zhou M, Lin L, Huang Z, Sun L, Shi M, Liao W. Impact of liver tumor percutaneous radiofrequency ablation on circulating tumor cells. Oncol Lett 2018;16:2839-50. [PMID: 30127870 DOI: 10.3892/ol.2018.9019] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
32 Hassanpour S, Hasanzadeh M. Label-free electrochemical-immunoassay of cancer biomarkers: Recent progress and challenges in the efficient diagnosis of cancer employing electroanalysis and based on point of care (POC). Microchemical Journal 2021;168:106424. [DOI: 10.1016/j.microc.2021.106424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Noritake H, Kobayashi Y, Ooba Y, Kitsugi K, Shimoyama S, Yamazaki S, Chida T, Watanabe S, Kawata K, Suda T. Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients. ISRN Hepatol 2014;2014:875140. [PMID: 27335844 DOI: 10.1155/2014/875140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Reyes R, Peris P, Monegal A, Fuster D, Guañabens N. Vertebral "clover" scintigraphic image in a vertebral metastasis misdiagnosed with Paget's disease. Clin Rheumatol 2008;27:1585-6. [PMID: 18766427 DOI: 10.1007/s10067-008-1001-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
35 Attallah AM, Omran MM, Attallah AA, Abdallah SO, Farid K, Darwish H, El-Dosoky I, Shaker YM. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer 2013;109:1657-65. [PMID: 23982602 DOI: 10.1038/bjc.2013.481] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
36 Sekine S, Ogawa R, Ito R, Hiraoka N, McManus MT, Kanai Y, Hebrok M. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 2009;136:2304-2315.e1-4. [PMID: 19272382 DOI: 10.1053/j.gastro.2009.02.067] [Cited by in Crossref: 127] [Cited by in F6Publishing: 119] [Article Influence: 9.8] [Reference Citation Analysis]
37 Ma XL, Gao XH, Gong ZJ, Wu J, Tian L, Zhang CY, Zhou Y, Sun YF, Hu B, Qiu SJ, Zhou J, Fan J, Guo W, Yang XR. Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. Oncotarget 2016;7:70654-68. [PMID: 27683106 DOI: 10.18632/oncotarget.12203] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
38 Chang S, Chen B, Wang X, Wu K, Sun Y. Long non-coding RNA XIST regulates PTEN expression by sponging miR-181a and promotes hepatocellular carcinoma progression. BMC Cancer 2017;17:248. [PMID: 28388883 DOI: 10.1186/s12885-017-3216-6] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 15.8] [Reference Citation Analysis]
39 Fang M, Dewaele S, Zhao YP, Stärkel P, Vanhooren V, Chen YM, Ji X, Luo M, Sun BM, Horsmans Y. Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat. Mol Cancer. 2010;9:215. [PMID: 20704698 DOI: 10.1186/1476-4598-9-215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
40 Yang Y, Zhu R. Diagnostic value of circulating microRNAs for hepatocellular carcinoma. Mol Biol Rep 2014;41:6919-29. [PMID: 25030834 DOI: 10.1007/s11033-014-3578-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
41 Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, Huang SF, Chui AK, Law DJ, Li YG. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol. 2003;162:1823-1829. [PMID: 12759240 DOI: 10.1016/s0002-9440(10)64317-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
42 Wang K, Guo WX, Li N, Gao CF, Shi J, Tang YF, Shen F, Wu MC, Liu SR, Cheng SQ. Serum LncRNAs Profiles Serve as Novel Potential Biomarkers for the Diagnosis of HBV-Positive Hepatocellular Carcinoma. PLoS One 2015;10:e0144934. [PMID: 26674525 DOI: 10.1371/journal.pone.0144934] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
43 Cui W, Gu F, Hu KQ. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009; 15(16): 1943-1950 [PMID: 19399925 DOI: 10.3748/wjg.15.1943] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
44 DiStefano JK. Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. Noncoding RNA Res 2017;2:129-36. [PMID: 30159431 DOI: 10.1016/j.ncrna.2017.11.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
45 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.2165/00066982-200408040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
46 He M, Wu C, Xu J, Guo H, Yang H, Zhang X, Sun J, Yu D, Zhou L, Peng T, He Y, Gao Y, Yuan J, Deng Q, Dai X, Tan A, Feng Y, Zhang H, Min X, Yang X, Zhu J, Zhai K, Chang J, Qin X, Tan W, Hu Y, Lang M, Tao S, Li Y, Li Y, Feng J, Li D, Kim ST, Zhang S, Zhang H, Zheng SL, Gui L, Wang Y, Wei S, Wang F, Fang W, Liang Y, Zhai Y, Chen W, Miao X, Zhou G, Hu FB, Lin D, Mo Z, Wu T. A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein and their associations with cancer risk. Gut 2014;63:143-51. [PMID: 23300138 DOI: 10.1136/gutjnl-2012-303434] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.0] [Reference Citation Analysis]
47 Gao XH, Zhang SS, Chen H, Wang YH, Yuan CH, Wang FB. Systemic Hepatic-Damage Index for Predicting the Prognosis of Hepatocellular Carcinoma after Curative Resection. Front Physiol 2017;8:480. [PMID: 28769812 DOI: 10.3389/fphys.2017.00480] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
48 Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004;99:860-5. [PMID: 15128351 DOI: 10.1111/j.1572-0241.2004.04152.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 113] [Article Influence: 6.5] [Reference Citation Analysis]
49 Kimura A, Sogawa K, Satoh M, Kodera Y, Yokosuka O, Tomonaga T, Nomura F. The application of a three-step serum proteome analysis for the discovery and identification of novel biomarkers of hepatocellular carcinoma. Int J Proteomics 2012;2012:623190. [PMID: 22957256 DOI: 10.1155/2012/623190] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
50 Zhao L, Mou DC, Peng JR, Huang L, Wu ZA, Leng XS. Diagnostic value of cancer-testis antigen mRNA in peripheral blood from hepatocellular carcinoma patients. World J Gastroenterol 2010; 16(32): 4072-4078 [PMID: 20731022 DOI: 10.3748/wjg.v16.i32.4072] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
51 Maass T, Sfakianakis I, Staib F, Krupp M, Galle PR, Teufel A. Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics. 2010;11:261-268. [PMID: 21119890 DOI: 10.2174/138920210791233063] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
52 Nwokediuko SC, Uchenna I, Esther O, Okechukwu O, Augustine O, Charity A. Relatively Long Survival in Hepatocellular Carcinoma Presenting With Carcinoid Syndrome. Gastroenterology Res 2010;3:46-9. [PMID: 27956985 DOI: 10.4021/gr2010.02.171w] [Reference Citation Analysis]
53 Guo J, Tang Q. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. Cancer Gene Ther. 2021;. [PMID: 33500535 DOI: 10.1038/s41417-020-00259-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Abdalla MA, Haj-Ahmad Y. Promising Candidate Urinary MicroRNA Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer. 2012;3:19-31. [PMID: 22211142 DOI: 10.7150/jca.3.19] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 7.3] [Reference Citation Analysis]
55 Kuang SY, Jackson PE, Wang JB, Lu PX, Muñoz A, Qian GS, Kensler TW, Groopman JD. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc Natl Acad Sci U S A 2004;101:3575-80. [PMID: 14990795 DOI: 10.1073/pnas.0308232100] [Cited by in Crossref: 124] [Cited by in F6Publishing: 113] [Article Influence: 6.9] [Reference Citation Analysis]
56 Abdalla MA, Haj-Ahmad Y. Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J Cancer. 2012;3:390-403. [PMID: 23074380 DOI: 10.7150/jca.4280] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
57 Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO. Gene expression patterns in human liver cancers. Mol Biol Cell. 2002;13:1929-1939. [PMID: 12058060 DOI: 10.1091/mbc.02-02-0023.] [Cited by in Crossref: 206] [Cited by in F6Publishing: 106] [Article Influence: 10.3] [Reference Citation Analysis]
58 Liu D, Luo Y, Chen L, Chen L, Zuo D, Li Y, Zhang X, Wu J, Xi Q, Li G, Qi L, Yue X, Zhang X, Sun Z, Zhang N, Song T, Lu W, Guo H. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study. Cancer Biol Med 2021;18:256-70. [PMID: 33628599 DOI: 10.20892/j.issn.2095-3941.2020.0207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Horvath A, Folhoffer A, Lakatos PL, Halász J, Illyés G, Schaff Z, Hantos MB, Tekes K, Szalay F. Rising plasma nociceptin level during development of HCC: A case report. World J Gastroenterol 2004; 10(1): 152-154 [PMID: 14695788 DOI: 10.3748/wjg.v10.i1.152] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
60 Ogasawara S, Nakayama M, Akiba J, Kusano H, Yano H. Effect of sorafenib on des-γ-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line. Oncol Lett 2017;14:2170-6. [PMID: 28781657 DOI: 10.3892/ol.2017.6451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Ha SY, Kim JH, Yang JW, Kim J, Kim B, Park CK. The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis. Cancer Res Treat 2016;48:1065-73. [PMID: 26511806 DOI: 10.4143/crt.2015.302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
62 Luo L, Chen L, Ke K, Zhao B, Wang L, Zhang C, Wang F, Liao N, Zheng X, Liu X, Wang Y, Liu J. High expression levels of CLEC4M indicate poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2020;19:1711-20. [PMID: 32194663 DOI: 10.3892/ol.2020.11294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Chang Y, Tao LW, Chen XP, Zhou XM, Song YH, Huang J, Zhang Q, Lin JS. Specificity and significance of expression of imprinted gene PEG10 in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2005; 13(12): 1408-1411 [DOI: 10.11569/wcjd.v13.i12.1408] [Reference Citation Analysis]
64 Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol. 2012;39:461-472. [PMID: 22846863 DOI: 10.1053/j.seminoncol.2012.05.011] [Cited by in Crossref: 135] [Cited by in F6Publishing: 131] [Article Influence: 13.5] [Reference Citation Analysis]
65 Fu YP, Yi Y, Huang JL, Jing CY, Sun J, Ni XC, Lu ZF, Cao Y, Zhou J, Fan J, Qiu SJ. Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. Oncologist 2017;22:561-9. [PMID: 28438885 DOI: 10.1634/theoncologist.2016-0231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
66 Fu Y, Xu X, Huang D, Cui D, Liu L, Liu J, He Z, Liu J, Zheng S, Luo Y. Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial. EBioMedicine. 2017;24:56-63. [PMID: 28939487 DOI: 10.1016/j.ebiom.2017.09.007.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF, Hampton GM. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA. 2003;100:3410-3415. [PMID: 12624183 DOI: 10.1073/pnas.0530278100] [Cited by in Crossref: 318] [Cited by in F6Publishing: 263] [Article Influence: 16.7] [Reference Citation Analysis]
68 Hu J, Xu Y, Shen ZZ, Wang Z, Lu Q, Yang GH, Ding ZB, Fan J, Zhou J. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol. 2009;135:1359-1367. [PMID: 19350273 DOI: 10.1007/s00432-009-0577-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
69 Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K. Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour Biol 2014;35:2497-502. [PMID: 24163059 DOI: 10.1007/s13277-013-1330-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
70 Chávez-López MG, Zúñiga-García V, Pérez-Carreón JI, Avalos-Fuentes A, Escobar Y, Camacho J. Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma. Biologics 2016;10:139-48. [PMID: 27703327 DOI: 10.2147/BTT.S87402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
71 Ye X, Li C, Zu X, Lin M, Liu Q, Liu J, Xu G, Chen Z, Xu Y, Liu L, Luo D, Cao Z, Shi G, Feng Z, Deng H, Liao Q, Cai C, Liao DF, Wang J, Jin J, Cao D. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma. Hepatology 2019;69:2489-501. [PMID: 30672601 DOI: 10.1002/hep.30519] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
72 Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E, Shiratori Y. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101:2038-43. [PMID: 16848811 DOI: 10.1111/j.1572-0241.2006.00681.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 96] [Article Influence: 6.9] [Reference Citation Analysis]
73 Gad A, Tanaka E, Matsumoto A, Wahab MAE, Serwah AEH, Attia F, Ali K, Hassouba H, el-Deeb AER, Ichijyo T, Umemura T, Muto H, Yoshizawa K, Kiyosawa K. Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma. World J Gastroenterol 2005; 11(42): 6607-6612 [PMID: 16425352 DOI: 10.3748/wjg.v11.i42.6607] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
74 Teng M, Pirrie S, Ward DG, Assi LK, Hughes RG, Stocken D, Johnson PJ. Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma. Br J Cancer. 2014;110:2277-2282. [PMID: 24603305 DOI: 10.1038/bjc.2014.121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
75 Abdel-Hamid NM, Mohafez OM, Nazmy MH, Farhan A, Thabet K. The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinoma. Environ Health Prev Med 2015;20:195-203. [PMID: 25726025 DOI: 10.1007/s12199-015-0451-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
76 Isaac A, Mohamed SM, Ahmed OA, Hassan AGM, Rasmy HS. Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00078-5] [Reference Citation Analysis]
77 Paradis V, Degos F, Dargère D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A, Delforge D, Cubizolles M, Laurendeau I, Bedossa P. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005;41:40-7. [PMID: 15690480 DOI: 10.1002/hep.20505] [Cited by in Crossref: 176] [Cited by in F6Publishing: 154] [Article Influence: 10.4] [Reference Citation Analysis]
78 Kang X, Sun L, Guo K, Shu H, Yao J, Qin X, Liu Y. Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS. J Cancer Res Clin Oncol 2010;136:1151-9. [PMID: 20130913 DOI: 10.1007/s00432-010-0762-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
79 Li PD, Chen P, Peng X, Ma C, Zhang WJ, Dai XF. HOXC6 predicts invasion and poor survival in hepatocellular carcinoma by driving epithelial-mesenchymal transition. Aging (Albany NY) 2018;10:115-30. [PMID: 29348394 DOI: 10.18632/aging.101363] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
80 Zhang LH, Ji JF. Molecular profiling of hepatocellular carcinomas by cDNA microarray. World J Gastroenterol 2005; 11(4): 463-468 [PMID: 15641127 DOI: 10.3748/wjg.v11.i4.463] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
81 Kim J, Jee Y. EMS-effect of Exercises with Music on Fatness and Biomarkers of Obese Elderly Women. Medicina (Kaunas) 2020;56:E158. [PMID: 32244777 DOI: 10.3390/medicina56040158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
82 Dos Santos A, Thiers V, Sar S, Derian N, Bensalem N, Yilmaz F, Bralet MP, Ducot B, Bréchot C, Demaugre F. Contribution of laser microdissection-based technology to proteomic analysis in hepatocellular carcinoma developing on cirrhosis. Proteomics Clin Appl 2007;1:545-54. [PMID: 21136705 DOI: 10.1002/prca.200600474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
83 Yee NS, Lee NP. Special Issue: Cancer Biomarkers and Targets in Digestive Organs. Biomedicines 2019;7:E3. [PMID: 30609746 DOI: 10.3390/biomedicines7010003] [Reference Citation Analysis]
84 Sun H, Chua MS, Yang D, Tsalenko A, Peter BJ, So S. Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma. Biomark Insights 2008;3:1-18. [PMID: 19578489 DOI: 10.4137/bmi.s595] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
85 Cui H, Hong C, Ying A, Yang X, Ren S. Ultrathin gold nanowire-functionalized carbon nanotubes for hybrid molecular sensing. ACS Nano 2013;7:7805-11. [PMID: 23987824 DOI: 10.1021/nn4027323] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
86 Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010;45:1272-1282. [PMID: 20625772 DOI: 10.1007/s00535-010-0278-5] [Cited by in Crossref: 115] [Cited by in F6Publishing: 110] [Article Influence: 9.6] [Reference Citation Analysis]
87 Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13(40): 5299-5305 [PMID: 17879397 DOI: 10.3748/wjg.v13.i40.5299] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
88 Fu S, Guo Z, Li S, Kuang M, Hu W, Hua Y, He X, Peng B. Prognostic value of preoperative serum gamma-glutamyltranspeptidase in patients with hepatocellular carcinoma after hepatectomy. Tumour Biol 2016;37:3433-40. [PMID: 26449826 DOI: 10.1007/s13277-015-4136-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
89 Dai LC, Yao X, Wang X, Niu SQ, Zhou LF, Fu FF, Yang SX, Ping JL. In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonucleotide-loaded nanoparticles. World J Gastroenterol 2009; 15(16): 1966-1972 [PMID: 19399928 DOI: 10.3748/wjg.15.1966] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
90 Wang K, Bai Y, Chen S, Huang J, Yuan J, Chen W, Yao P, Miao X, Wang Y, Liang Y, Zhang X, He M, Yang H, Wei Q, Guo H, Wei S. Genetic correction improves prediction efficiency of serum tumor biomarkers on digestive cancer risk in the elderly Chinese cohort study. Oncotarget 2018;9:7389-97. [PMID: 29484118 DOI: 10.18632/oncotarget.23205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
91 He M, Qin J, Zhai R, Wei X, Wang Q, Rong M, Jiang Z, Huang Y, Zhang Z. Detection and identification of NAP-2 as a biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach. Proteome Sci 2008;6:10. [PMID: 18331625 DOI: 10.1186/1477-5956-6-10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
92 Li J, Cheng ZJ, Liu Y, Yan ZL, Wang K, Wu D, Wan XY, Xia Y, Lau WY, Wu MC, Shen F. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget 2015;6:9551-63. [PMID: 25871387 DOI: 10.18632/oncotarget.3314] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
93 Li Y, Wu J, Zhang W, Zhang N, Guo H. Identification of serum CCL15 in hepatocellular carcinoma. Br J Cancer. 2013;108:99-106. [PMID: 23321514 DOI: 10.1038/bjc.2012.494] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
94 Khairil Anwar NA, Mohd Nazri MN, Murtadha AH, Mohd Adzemi ER, Balakrishnan V, Mustaffa KMF, Tengku Din TADA, Yahya MM, Haron J, Mokshtar NF. Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. Acta Biochim Biophys Sin (Shanghai) 2021;53:961-78. [PMID: 34180502 DOI: 10.1093/abbs/gmab077] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Imai N, Kinoshita A, Onoda H, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Tajiri H. Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. Clin Transl Oncol 2013;15:575-81. [PMID: 23263911 DOI: 10.1007/s12094-012-0976-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
96 Anderson PW, Tennant BC, Lee Z. Cross-species hybridization of woodchuck hepatitis virus-induced hepatocellular carcinoma using human oligonucleotide microarrays. World J Gastroenterol 2006; 12(29): 4646-4651 [PMID: 16937433 DOI: 10.3748/wjg.v12.i29.4646] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
97 Cheng K, Shi J, Liu Z, Jia Y, Qin Q, Zhang H, Wan S, Niu Z, Lu L, Sun J, Xue J, Lu C, Wei X, Guo L, Zhang F, Zhou D, Tang Y, Hu Y, Huang Y, Chen Y, Lau WY, Cheng S, Liu S. A panel of five plasma proteins for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma in individuals at risk. EBioMedicine 2020;52:102638. [PMID: 32014820 DOI: 10.1016/j.ebiom.2020.102638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
98 Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016;7:69916-69926. [PMID: 27655712 DOI: 10.18632/oncotarget.12066] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
99 Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY, Wang XW. Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology 2014;60:872-83. [PMID: 24798303 DOI: 10.1002/hep.27200] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 9.3] [Reference Citation Analysis]
100 Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford). 2005;7:26-34. [PMID: 18333158 DOI: 10.1080/13651820410024049] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 11.0] [Reference Citation Analysis]
101 Yang PC, Ho CM, Hu RH, Ho MC, Wu YM, Lee PH. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol 2016; 8(31): 1309-1317 [PMID: 27872682 DOI: 10.4254/wjh.v8.i31.1309] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
102 Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K, Akira S, Brenner DA, Seki E. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci USA. 2010;107:844-849. [PMID: 20080763 DOI: 10.1073/pnas.0909781107] [Cited by in Crossref: 192] [Cited by in F6Publishing: 190] [Article Influence: 14.8] [Reference Citation Analysis]
103 Wang JH, Wei W, Guo ZX, Shi M, Guo RP. Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. J Transl Med 2015;13:41. [PMID: 25638165 DOI: 10.1186/s12967-015-0396-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
104 Ma J, Jin J, Lu H, Zhang J, Li Y, Cai X. Exonuclease 1 is a Potential Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:889414. [DOI: 10.3389/fmolb.2022.889414] [Reference Citation Analysis]
105 Wang JH, Wei W, Xu J, Guo ZX, Xiao CZ, Zhang YF, Jian PE, Wu XL, Shi M, Guo RP. Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma. Oncotarget 2015;6:35116-28. [PMID: 26375669 DOI: 10.18632/oncotarget.5057] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
106 Bao L, Chandra PK, Moroz K, Zhang X, Thung SN, Wu T, Dash S. Impaired autophagy response in human hepatocellular carcinoma. Exp Mol Pathol 2014;96:149-54. [PMID: 24369267 DOI: 10.1016/j.yexmp.2013.12.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.1] [Reference Citation Analysis]
107 da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014;31:264. [PMID: 25273866 DOI: 10.1007/s12032-014-0264-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
108 Lu CY, Chen SY, Peng HL, Kan PY, Chang WC, Yen CJ. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma. Oncotarget 2017;8:6406-18. [PMID: 28031532 DOI: 10.18632/oncotarget.14115] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
109 Liu HH, Fang Y, Wang JW, Yuan XD, Fan YC, Gao S, Han LY, Wang K. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma. Medicine (Baltimore) 2020;99:e20326. [PMID: 32443384 DOI: 10.1097/MD.0000000000020326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Mohamed BF, Serag WM, Abdelal RM, Elsergany HF. S100A14 protein as diagnostic and prognostic marker in hepatocellular carcinoma. Egypt Liver Journal 2019;9. [DOI: 10.1186/s43066-019-0015-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
111 Hu H, Quintana J, Weissleder R, Parangi S, Miller M. Deciphering albumin-directed drug delivery by imaging. Adv Drug Deliv Rev 2022;185:114237. [PMID: 35364124 DOI: 10.1016/j.addr.2022.114237] [Reference Citation Analysis]
112 Mehinovic L, Islamagic E, Husic-Selimovic A, Kurtovic-Kozaric A, Vukobrat-Bijedic Z, Suljevic D. Evaluation of Diagnostic Efficiency of Alpha-Fetoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Single-Center Experience. Open Access Maced J Med Sci 2018;6:1668-73. [PMID: 30337985 DOI: 10.3889/oamjms.2018.344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
113 Gad A, Tanaka E, Matsumoto A, El-hamid Serwah A, Attia F, Hassan A, Sanny A, Ali K, Abbas A, El-raoof El-deeb A, Sun XH, Umemura T, Ichijo T, Ehara T, Yoshizawa K, Kiyosawa K. Ethnicity affects the diagnostic validity of alpha-fetoprotein in hepatocellular carcinoma. Asia-Pacific J Clinical Oncology 2005;1:64-70. [DOI: 10.1111/j.1743-7563.2005.00017.x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
114 Ji J, Liu L, Jiang F, Wen X, Zhang Y, Li S, Lou J, Wang Y, Liu N, Guo Q, Jia Y, Gao C. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China. J Clin Lab Anal 2021;35:e24013. [PMID: 34590755 DOI: 10.1002/jcla.24013] [Reference Citation Analysis]
115 Jasirwan COM, Fahira A, Siregar L, Loho I. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. BMC Gastroenterol 2020;20:215. [PMID: 32646378 DOI: 10.1186/s12876-020-01365-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
116 Park H, Park JY. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. Biomed Res Int. 2013;2013:310427. [PMID: 24455683 DOI: 10.1155/2013/310427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
117 Su WL, Chuang SC, Wang YC, Chen LA, Huang JW, Chang WT, Wang SN, Lee KT, Lin CS, Kuo KK. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma. Cancer Biomark 2020;28:341-50. [PMID: 32390596 DOI: 10.3233/CBM-190507] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Fu Y, Xu X, Huang D, Cui D, Liu L, Liu J, He Z, Zheng S, Luo Y. Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial. EBioMedicine. 2017;24:56-63. [PMID: 28939487 DOI: 10.1016/j.ebiom.2017.09.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
119 Ji J, Wang H, Li Y, Zheng L, Yin Y, Zou Z, Zhou F, Zhou W, Shen F, Gao C. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. PLoS One 2016;11:e0153227. [PMID: 27070780 DOI: 10.1371/journal.pone.0153227] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
120 Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, Wang WT, Xu MQ, Yang JY. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol 2013; 19(11): 1811-1819 [PMID: 23555170 DOI: 10.3748/wjg.v19.i11.1811] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 73] [Article Influence: 8.4] [Reference Citation Analysis]
121 Chen F, Zhong Z, Tan HY, Wang N, Feng Y. The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. Cancers (Basel) 2020;12:E1734. [PMID: 32610709 DOI: 10.3390/cancers12071734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]